Heparin cofactor II–thrombin complex: A biomarker of MPS disease
Derrick R. Randall(University of British Columbia), L. Clarke(University of British Columbia), Tony Rupar(Western University), Graham Sinclair, Anita C. Thomas(University of British Columbia), Silvia Stockler(University of British Columbia), Grant A. Mitchell(CURE International UK), Karen E. Colobong(University of British Columbia), Elly Hetty(University of British Columbia), Olaf A. Bodamer(Broad Institute), Harmony Hemmelgarn(University of British Columbia), Alicia K.J. Chan(University of Alberta), Paul M. Fernhoff, Serge B. Melançon(Université de Montréal), Robin Casey(University of Calgary), Barbara Volkmar(Paracelsus Medical University)
Cited by 62
Related Papers
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|823
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|535
ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORF
|Nature Genetics|2000|438
Excess of De Novo Deleterious Mutations in Genes Associated with Glutamatergic Systems in Nonsyndromic Intellectual Disability
|The American Journal of Human Genetics|2011|352
Mutations in SLC39A14 disrupt manganese homeostasis and cause childhood-onset parkinsonism–dystonia
|Nature Communications|2016|326